MR-contrast enhanced mammography (CEM) for follow-up of breast cancer patients: a “pros and cons” debate
European Radiology · 2024
DOI: 10.1007/s00330-024-10684-w ↗Kurz gefasst
Fachartikel in der Zeitschrift European Radiology, 2024. Verfasst von Julia Camps-Herrero und 2 weiteren Autor:innen. Beteiligte Einrichtung: Ribera Salud Hospitals, Valencia, Spain. Hauptthemen laut MEDLINE: Breast Neoplasms, Contrast Media, Magnetic Resonance Imaging, Mammography. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Women with a personal history of breast cancer (PHBC) are at an increased risk of either a local recurrence or a new primary breast cancer. Thus, surveillance is essential for the detection of recurrent disease at the earliest possible stage, allowing for prompt treatment, and potentially improving overall survival. Nowadays, mammography follow-up is the only surveillance imaging technique recommended by international guidelines. Nevertheless, sensitivity of mammography is lower after breast cancer treatment, particularly during the first 5 years, due to increased density or post-treatment changes. Contrast-enhanced breast imaging techniques, such as MRI or contrast-enhanced mammography (CEM), are very sensitive to detect malignant enhancement, especially in dense breasts. This Special Report will provide arguments in favor of and against breast cancer follow-up with MRI or CEM, in a debate style between experts in Breast Imaging. Finally, the scientific points of pros and cons arguments will be summarized to help objectively decide the best follow-up strategy for women with a personal history of breast cancer. CLINICAL RELEVANCE STATEMENT: A personalized approach to follow-up imaging after conservative breast cancer treatment could optimize patient outcomes, using mammography as a baseline for most patients, and MRI or CEM selectively in patients with higher risks for a recurrence. KEY POINTS: • Women with a personal history of breast cancer are at an increased risk of either a local recurrence or a new primary breast cancer. • Breast cancer survivors may benefit from additional imaging with MRI/CEM, in case of increased risk of a second breast cancer, with dense breasts or a cancer diagnosis before age 50 years. • As survival after local recurrence seems to depend on the initial stage at diagnosis, imaging should be more focused on detecting tumors in the earliest stages.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ribera Salud Hospitals, Valencia, Spain.
- Department of Radiology, University Medical Centre Utrecht, Utrecht, the Netherlands.
- Imaging Department, Gustave Roussy Cancer Campus, Villejuif, France. corinne.balleyguier@gustaveroussy.fr.
- BIOMAPS, UMR 1281, Université Paris-Saclay, 94800, Villejuif, France. corinne.balleyguier@gustaveroussy.fr.
Zitieren
APA
Camps-Herrero, J., Pijnappel, R., & Balleyguier, C. (2024). MR-contrast enhanced mammography (CEM) for follow-up of breast cancer patients: a “pros and cons” debate. European Radiology. https://doi.org/10.1007/s00330-024-10684-w
Vancouver
Camps-Herrero J, Pijnappel R, Balleyguier C. MR-contrast enhanced mammography (CEM) for follow-up of breast cancer patients: a “pros and cons” debate. European Radiology. 2024. doi:10.1007/s00330-024-10684-w
BibTeX
@article{CampsHerrero2024,
author = {Camps-Herrero, Julia and Pijnappel, Ruud and Balleyguier, Corinne},
title = {MR-contrast enhanced mammography (CEM) for follow-up of breast cancer patients: a “pros and cons” debate},
journal = {European Radiology},
year = {2024},
doi = {10.1007/s00330-024-10684-w}
}
EUVIMED